Updates are available Correction dated 2019-05-29
Click to view Correction: https://doi.org/10.1007/s11682-019-00125-4
-
Authors
Biazoli, Claudinei Eduardo Jr
Salum, Giovanni Abrahão
Gadelha, Ary
Rebello, Keila
Moura, Luciana Monteiro
Pan, Pedro Mario
Brietzke, Elisa
Miguel, Euripedes Constantino
Rohde, Luis Augusto
Bressan, Rodrigo Affonseca
Jackowski, Andrea Parolin
Sato, João Ricardo
-
Funding
Funding for this research was provided by:
FAPESP (2013/10498-6 and 2013/00506-1, 2013/08531-5, 2008/57896-8)
CNPq (573974/2008-0 and 442026/2014-5)
- License Information
-
More Information
Article History
First Online: 13 March 2019
Change Date: 29 May 2019
Change Type: Correction
Change Details: The original version of this article contained mistakes. The surname of Elisa Brietzke was misspelled as “Brietske”.
Compliance with ethical standards
:
: Dr. Luis Augusto Rohde is supported by grants from CNPq and has been on the speakers’ bureau/advisory board and/or acted as a consultant for Eli-Lilly, Janssen-Cilag, Novartis and Shire in the last three years. The ADHD and Juvenile Bipolar Disorder Outpatient Programs he chaired received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Eli-Lilly, Janssen-Cilag, Novartis, and Shire. He receives authorship royalties from Oxford Press and ArtMed. He has also received travel awards from Shire for his participation in the 2014 APA and 2015 WFADHD meetings. Dr. Rodrigo A. Bressan has been on the speakers’ bureau/advisory board of AstraZeneca, Bristol, Janssen and Lundbeck and has received research grants from Janssen, Eli Lilly, Lundbeck, Novartis, Roche, FAPESP, CNPq, CAPES, Fundação E.J. Safra and Fundação ABAHDS. He is a shareholder of Biomolecular Technology Ltd.
: Yes
: Yes
